EquityZen Growth Technology Fund LLC - Series 2040 (CIK: 0002050384) EDGAR, Information, Filings... CompaniesBIO.Com

EquityZen Growth Technology Fund LLC - Series 2040

Mailing address
30 BROAD STREET, SUITE 1200, NEW YORK, Delaware, 10004
Phone
1-877-490-6121
State location
New York
State of incorporation
Delaware
Fiscal year end
December 31
SIC
N/A
Filings
N/A

EquityZen Growth Technology Fund LLC - Series 2040 (CIK: 0002050384) is an American company incorporated in the state of New York. Head office is located at 30 BROAD STREET, SUITE 1200, NEW YORK, New York, 10004. Work in the industry N/A. EquityZen Growth Technology Fund LLC - Series 2040 is a public company and trade via Over-The-Counter (OTC).

Includes all SEC registration details as well as a list of all documents (S-1, Prospectus, Current Reports, 8-K, 10K, Annual Reports) filed by EquityZen Growth Technology Fund LLC - Series 2040

Filings	Format	Description	Filed/Effective	File/Film Number
D	Document	Acc-no: 0002050384-25-000001 (33 Act) Size: KB	Jul-23-2025	021-552591 251142689

Recent 20 filings. View all EquityZen Growth Technology Fund LLC - Series 2040 filings

Overall rating 5.0

Aug 22, 2022

Catherine

Thanks I look forward to using the product to improve my skin tone

Aug 22, 2022

Jean Bishop

Very good communication and delivery made within the timeframe I was advised of

Aug 22, 2022

Samuel Ejimofor

It's being easier working on the website. And I recommend, it's a great website

EquityZen Growth Technology Fund LLC - Series 2040 overview
EquityZen Growth Technology Fund LLC - Series 2040 job
EquityZen Growth Technology Fund LLC - Series 2040 stock
EquityZen Growth Technology Fund LLC - Series 2040 ownership
EquityZen Growth Technology Fund LLC - Series 2040 CEO
EquityZen Growth Technology Fund LLC - Series 2040 documents

Disclaimer: The information on the Service is provided with the understanding that the Company is not herein engaged in rendering legal, accounting, tax, or other professional advice and services. As such, it should not be used as a substitute for consultation with professional accounting, tax, legal or other competent advisers.